Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission

被引:77
作者
Eckstein, Anja K.
Lax, Hildegard
Loesch, Christian
Glowacka, Diana
Plicht, Marco
Mann, Klaus
Esser, Joachim
Morgenthaler, Nils G.
机构
[1] Univ Essen Gesamthsch, Dept Ophthalmol, Essen, Germany
[2] Univ Essen Gesamthsch, Inst Med Informat Biometry & Epidemiol, Essen, Germany
[3] Univ Essen Gesamthsch, Dept Med, Div Endocrinol, Essen, Germany
[4] Univ Med Berlin, Inst Expt Endorinol & Endokrinol Forschungszentru, Berlin, Germany
关键词
D O I
10.1111/j.1365-2265.2007.02933.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the relationship between severity of Graves' ophthalmopathy (GO) and relapse/remission rate of associated thyroid disease. Patients and methods One hundred and fifty-eight patients with Graves' disease (GD) were seen within the first 6-12 months after the onset of GO and were followed for at least 18 months. During treatment, GO was classified as mild (n = 65) or severe course (n = 93) by severity and activity scores. All patients received standard anti-thyroid drug (ATD) treatment for 1 year, and in cases of relapse another cycle of ATD, thyroidectomy or radioiodine therapy. Results Following ATD treatment, 27 patients (42%) with a mild course of GO went into thyroid disease remission, while only seven (8%) patients with a severe course of GO achieved remission (P < 0.0001). Eventually, 32 patients (49%) with a mild course needed definitive thyroid therapy and the remaining 9% preferred another cycle of ATD. However, among patients with a severe GO course, 84% needed definitive therapy (P < 0.0001) and 8% opted for another course of ATD treatment. The probability of relapse could also be predicted by TBII levels 12 months after initiation of ATD therapy, as 96.8% of patients with TBII levels above 7.5 IU/l relapsed (odds ratio 24.3). Conclusion Patients with severe GO and high TBII are unlikely to go into remission. This allows early decision-making regarding definitive treatment of the thyroid in GD patients with severe GO or very high TBII levels.
引用
收藏
页码:607 / 612
页数:6
相关论文
共 22 条
[1]   An update on the pharmacological management of hyperthyroidism due to Graves' disease [J].
Bartalena, L ;
Tanda, ML ;
Bogazzi, F ;
Piantanida, E ;
Lai, A ;
Martino, E .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) :851-861
[2]   An update on medical management of Graves' ophthalmopathy [J].
Bartalena, L ;
Marcocci, C ;
Tanda, ML ;
Piantanida, E ;
Lai, A ;
Marinò, M ;
Pinchera, A .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (05) :469-478
[3]   Relationship between management of hyperthyroidism and course of the ophthalmopathy [J].
Bartalena, L ;
Tanda, ML ;
Piantanida, E ;
Lai, A ;
Pinchera, A .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (03) :288-294
[4]   Cigarette smoking and treatment outcomes in Graves ophthalmopathy [J].
Bartalena, L ;
Marcocci, C ;
Tanda, ML ;
Manetti, L ;
Dell'Unto, E ;
Bartolomei, MP ;
Nardi, M ;
Martino, E ;
Pinchera, A .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (08) :632-635
[5]   Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: Evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period [J].
Carella, C ;
Mazziotti, G ;
Sorvillo, F ;
Piscopo, M ;
Cioffi, M ;
Pilla, P ;
Nersita, R ;
Iorio, S ;
Amato, G ;
Braverman, LE ;
Roti, E .
THYROID, 2006, 16 (03) :295-302
[6]   Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease [J].
Costagliola, S ;
Morgenthaler, NG ;
Hoermann, R ;
Badenhoop, K ;
Struck, J ;
Freitag, D ;
Poertl, S ;
Weglöhner, W ;
Hollidt, JM ;
Quadbeck, B ;
Dumont, JE ;
Schumm-Draeger, PM ;
Bergmann, A ;
Mann, K ;
Vassart, G ;
Usadel, KH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :90-97
[7]   COMPARISON OF RA I-131 TREATMENT PROTOCOLS FOR GRAVES-DISEASE [J].
DEGROOT, LJ ;
MANGKLABRUKS, A ;
MCCORMICK, M .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1990, 13 (02) :111-118
[8]   Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies [J].
Eckstein, AK ;
Plicht, M ;
Lax, H ;
Hirche, H ;
Quadbeck, B ;
Mann, K ;
Steuhl, KP ;
Esser, J ;
Morgenthaler, NG .
CLINICAL ENDOCRINOLOGY, 2004, 61 (05) :612-618
[9]   Thyrotropin receptor autoantibodies are independent risk factors for graves' ophthalmopathy and help to predict severity and outcome of the disease [J].
Eckstein, Anja K. ;
Plicht, Marco ;
Lax, Hildegard ;
Neuhaeuser, Markus ;
Mann, Klaus ;
Lederbogen, Sebastian ;
Heckmann, Christian ;
Esser, Joachim ;
Morgenthaler, Nils G. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3464-3470
[10]  
Garrity J A, 1994, Curr Opin Ophthalmol, V5, P39